Oncobiologics Q2 2025 Earnings Report

Oncobiologics EPS Results

• Actual EPS: -$0.40
• Consensus EPS: -$0.55
• Beat/Miss: Beat by +$0.15
• One Year Ago EPS: N/A

Oncobiologics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.70 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oncobiologics Announcement Details

• Quarter: Q2 2025
• Date: 5/15/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 15, 2025
• Conference Call Time: 12:30PM ET

Oncobiologics (NASDAQ:OTLK) is a clinical‐stage biopharmaceutical company focused on the development of biosimilar therapies for oncology and autoimmune diseases. Founded in 2012 and headquartered in New Jersey, the company applies a tailored approach to protein engineering and cell line optimization to create high‐quality biosimilar candidates. Oncobiologics aims to provide more affordable therapeutic options by leveraging advanced biomanufacturing techniques and streamlined development pathways.

The company’s product pipeline includes several late‐stage biosimilar candidates designed to match reference biologics used in the treatment of cancer and chronic inflammatory disorders. Oncobiologics has established a strategic manufacturing partnership with a global contract development and manufacturing organization (CDMO), enabling scalable production of its lead candidates. The development program addresses key molecules with significant market demand, and the company has reported positive analytical and preclinical comparability results to date.

Oncobiologics serves a global footprint, targeting markets in North America, Europe and Asia-Pacific through a combination of in‐license agreements and commercialization partnerships. The company is working with regional distributors and pharmaceutical collaborators to navigate regulatory approvals and to facilitate market access upon approval. This geographic strategy is designed to accelerate product launches and to enable broad patient access to its biosimilar therapies.

The company is led by Executive Chairman Satish Hegde, Ph.D., and President & CEO Pratibha Sinha, who bring extensive experience in biopharmaceutical development and regulatory affairs. Supported by a leadership team of seasoned professionals in research, manufacturing and commercialization, Oncobiologics continues to advance its biosimilar portfolio through clinical trials and regulatory interactions. The company’s management emphasizes scientific rigor and cost‐effective development to meet the evolving needs of healthcare systems worldwide.